Accordingly, combination therapy using small-molecule drugs and MSC-sTRAIL could sensitized tumor cells to TRAIL, and also decreased the concerns of side-effect-initiating cytokine production (Mohr et al., 2019). This evidence concerns the gene TNFSF10 and neoplasm.